Ann Arbor, MI., – September 12, 2022 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that it has contracted Jeff Dorton, a top textile expert to assist the Company in developing new and innovative yarns and fabrics utilizing Dragon Silk™.

Kraig Labs is leveraging Mr. Dorton’s expertise and proven record of innovation in textiles to create new and exciting composite yarns and fabrics utilizing spider silk. The initial customer for these yarns and fabrics will be Spydasilk Enterprises, the Company’s joint venture apparel brand, headquartered in Singapore. Following the launch of Spydasilk apparel, the Company plans to expand collaboration with Mr. Dorton to create several additional yarns and textiles, for applications spanning the performance and luxury textiles market and beyond.

Mr. Dorton brings a passion for material development, a proven track record of innovation, and a wealth of experience working with some of the best textile mills worldwide. He has led some of those most disruptive innovations in next-generation textiles that permeate the performance wear segment.

Utilizing his extensive network of mills and spinners around the globe, Mr. Dorton is currently working to drive the manufacture of the first spider silk fabrics.

“I have known Jeff since his time with The North Face, and I am thrilled to partner with him to create Kraig Labs’ first custom yarns and fabrics. Jeff is a highly regarded textile expert with a storied history of developing new textile technologies. He has directed key initiatives for some of the planet’s biggest brands, and we can’t wait to see what we can do together. While his ability to develop high-performance yarns and fabrics may be unmatched, we share Jeff’s passion for sustainability and textiles that are functional and desirable,” stated Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Jeff Dorton

Dorton is Vice President of Product Development and Material Innovation at LifeLabs Design. Previously he directed material innovation efforts for The North Face and Under Armour.

Dorton’s career highlights include developing Intellectual Property in fabric and insulation commercialized by leading performance wear brands around the globe. He has balanced this work in innovation with a solid commitment to environmental responsibility and drive to sustainability. Dorton led initial efforts to develop Nano spun membrane called FutureLight, the most advanced fabric and largest commercial launch in The North Face’s (TNF) history. Dorton expanded the franchise offering of “Thermoball” insulation through construction and material innovation for TNF. He coordinated with the sustainability team at VF Corporation to create the Responsible Down Standard that was later gifted to Textile Exchange to ensure ethical and sustainable sourcing for natural insulations. Dorton assisted in moving the entire supply chain at TNF to a more eco-friendly C0 DWR finish and shifted over 80% of fabrics into recycled content.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 17, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has now been granted a business license to begin operations in Lam Dong Province. 

The newly established business license and facility in Lam Dong Province are part of the Company’s expansion into the Vietnamese highlands, the center of silk production in Vietnam. The highlands of Lam Dong Province offer temperate climates ideal for silkworm rearing and ready access to the cocoon and silk spinning facilities currently producing several hundred metric tons of mundane silk per year. 

In June, management from Kraig Labs traveled to Lam Dong for meetings with officials from the Lam Dong Agro-Forestry Research Experiment Center (LAREC) to assess the opportunities to expand silk production into the province and to tour the regional support infrastructure.   The LAREC operates as the authority in Vietnamese sericulture, maintaining 47 unique species of Vietnamese silkworms. The LAREC has developed multiple varieties of mulberry, including S7-CB, which has doubled production yields, from about 25-30 metric tons of foliage per hectare, for standard mulberry, to 50-60 tons of foliage per hectare, for the S7-CB mulberry strains. Kraig Labs planted with S7-CB mulberry at its facilities in Quang Nam, which has resulted in similar improvements.

The Company’s Vietnamese headquarters will remain in Quang Nam at its breeding and production center. This facility was recently featured as part of the Company’s behind-the-scenes video series, www.kraiglabs.com/videos. The Quang Nam facility is designed to produce and supply all of the Company’s proprietary silkworm eggs for in-house and 3^rd party contract manufacturing.

“Lam Dong is the center of silk production in Vietnam. We are pleased to report that, with the granting of this business license, Kraig Labs and our specialized spider silk silkworm technologies are now being woven into the proud history and bright future of Vietnamese sericulture,” said Company COO Jon Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 4, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of the second behind the scenes look into its recombinant spider silk production operations. This video brings the viewer inside the laboratories at its R&D facility in the U.S. and its quality control lab at its production facility in Vietnam. 

This video tour edition highlights the laboratory facilities and the team of dedicated researchers and scientists creating and commercializing the world’s first cost-effective and eco-responsible spider silk.

“Our research and quality assurance teams are leading the way, creating and commercializing some of the most amazing materials on earth,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/xX6z_e7gyvA, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the rearing and breeding operations and the opportunity to meet some of the team creating tomorrow’s super fibers.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could,” “will” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – August 1, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that representatives of its apparel brand SpydaSilk^TM attended Vietnam’s premiere textile and garment industry exhibition, SaigonTex.

Since 1990, SaigonTex has brought together the largest collection of producers, suppliers, and buyers from Europe and Asia in the textile, fabric, and garment industry. Last week’s exhibition marked the event’s first return since 2019 after two years of COVID-19-related cancellations.   

The SpydaSilk team attended the Expo as part of its efforts to grow its network of suppliers. The team is working quickly to identify and partner with industry leaders capable of creating one-of-a-kind customer yarns and fabrics built upon Kraig Labs’ recombinant spider silk technologies. These new exclusive yarns and fabrics will be the foundation of SpydaSilk’s brand identity.    

“We are happy to see the return of SaigonTex, Vietnam’s premiere textile exhibition. The re-opening of this major international exhibition is evidence that the textile industry is roaring back. This event was a great opportunity for members of our SpydaSilk team to network with many new potential production partners as we work towards the first apparel launch,” said Company COO Jon Rice.

The Company expects to release the second video in its behind-the-scenes series taking viewers inside its spider silk production facilities next week. This episode will bring you inside the R&D labs at Kraig and Prodigy as the team works to create tomorrow’s super materials and monitors the performance and quality of current Dragon Silk^TM production.

For those who missed the first episode in this video series, it can be found at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where viewers can subscribe to be notified of future video releases in this series.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “will”, “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, Michigan., – July 20, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the release of a behind the scenes look into its silkworm breeding facility in Vietnam. This video is the first in a series designed to bring the viewer inside the Company’s recombinant spider silk production operations. 

This video tour edition highlights the breeding and egg production center that the Company established in Vietnam, to support in-house and third-party contract manufacturing of its eco-responsible and cost-effective spider silk.

Operated by its wholly owned Vietnamese subsidiary, the Company believes that this facility is now equipped to meet the production demand for its proprietary specialized spider silk silkworm eggs through 2025 and has the capacity to expand far beyond that.

“Our team has built out what we believe to be one of the most advanced silkworm breeding facilities in the world. We are excited to share these first behind-the-scenes looks into our operations and to bring the viewers along on this incredible journey bringing our eco-responsible cost-effective spider silk to the global consumer markets,” said Company COO Jon Rice.

Interested viewers can find the video at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://youtu.be/qeM2hzXbtRM, where they can subscribe to be notified of future video releases in this series.

In upcoming video releases, the Company expects to bring viewers along for tours inside the R&D and quality control labs as well as the feeding, rearing, and breeding operations.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Ann Arbor, MI – June 27, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk’s^TM first apparel line.

Over the course of multiple meetings between Kraig Labs, Kings Group, and the garment manufacturer, conducted while the Company’s COO was in Vietnam this month, the Company finalized its manufacturer choice for the first apparel launch under the Spydasilk^TM brand. 

The manufacturer selected has demonstrated its capacity and technical ability to deliver on Spydasilk’s vision for apparel that blends performance and elegance with its exclusive spider silk materials. With more than 20 years in business and its strong ties to Vietnam’s entire textile supply chain, this producer can leverage the capabilities of the best mills to bring the Spydailk brand to life. 

In partnership with Kings Group, the Company has already delivered its recombinant spider silk yarn and a non-spider silk fabric swatch for use in developing a brand new fabric built upon the performance and feel of the Company’s spider silk.

“Bringing the first products built on our spider silk technology to life is a critical step we are taking simultaneously with our planned increase in production through third-party contractors,” said Company COO, Jon Rice. “The network we have assembled to launch Spydasilk brings together top textile science, fashion, marketing, and branding experts. Our vision for the mass production and distribution of products built upon the amazing capabilities of spider silk is now quickly becoming a reality.”

Kraig Labs and Kings Group are simultaneously developing an accelerated product launch plan, including media, marketing, sales, and distribution systems for this first direct-to-consumer apparel launch.

The Company expects to continue to provide additional details and updates on the rapid advancements it is making under its business plan. Further information will be shared in press releases on advancements in production, quality control, and end market products over the coming days and weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Labs Launches the Critical Next Phases of its Business Plan, Expanded Recombinant Spider Silk Production in Collaboration with Third-Party Contractors

Ho Chi Minh City, Vietnam – June 21, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the completion of its third-party pilot production. As a result of this highly successful program, Kraig Labs will launch the critical next phases of its business plan and expand its recombinant spider silk production in collaboration with third-party contractors.

Key Kraig Labs management team members traveled to Vietnam to review the results of a series of pilot production runs completed by one of the silk production subcontractors the Company has been working with in preparation for entering the next phase of its business plan. The subcontractor pilot program exceeded management’s expectations to the point that Kraig Labs is now finalizing the terms of a 5-year production contract. This joint effort, by the subcontractor and Prodigy Textiles, the Company’s Vietnamese subsidiary, has already completed production of the raw recombinant spider silk needed for the first apparel launch under the Company’s jointly owned apparel brand, Spydasilk^TM.

Kraig Labs is on track to complete negotiations on the structure of expanded production with this contractor before Jon Rice, the Company’s Chief Operations Officer, returns to the US this week. Based on the results of these first pilot runs and the contractors’ production capacity, the Company is now on a path to producing metric tons of spider silk.

During this trip, the Company’s top scientist has also been evaluating and updating production and science processes at Prodigy Textiles. A focus of his work has been bringing state-of-the-art technology into our Vietnamese lab to reduce and eliminate mundane silkworm pathogens known to impact global silk production and inhibited the Company’s production growth. Our facility is now one of the most advanced sericulture labs in South East Asia and is already enhancing the quality of our operations.

The management team traveled over 2,700 miles since arriving in Vietnam. The Company met with three separate contract manufacturers, spanning from Da Nang to Ho Chi Minh City, who are vying to produce the Company’s specialized silk.

“The production capabilities demonstrated by the contract producer in these first runs have given us the raw spider silk necessary to bring our first finished garments to market and the confidence to aggressively push forward for exponential increases in silk output. With these successes, we are entering the next phase of our business plan, which includes rapid production expansion with subcontractors in parallel with the growth of our nascent joint venture apparel brand. Together, our teams from Kraig, Prodigy Textiles, and Spydasilk^TM are showing significant and tangible success on all fronts,” stated Rice

Kraig Labs anticipates issuing a series of additional updates on production expansion, Prodigy Textile’s laboratory developments, Spydasilk^TM, and other significant achievements shortly after the management team returns to the Company’s headquarters this week. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Management’s crowded Agenda includes meetings with Governmental Officials and intensive Factory Team Training

ANN ARBOR, Mich., – June 8, 2022– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, sends senior members of its US management and research team to Vietnam to support multiple aspects of operations focused on production expansion and development of end markets.

This trip marks the return to normal travel and the participating management team members have a packed agenda for this trip, following the lifting of travel restrictions.

Jon Rice, the Company’s Chief Operations Officer, will be traveling throughout Vietnam to support Kraig Labs’ production expansion and commercialization on several fronts. Rice will be meeting with government officials in multiple provinces to discuss additional lands for production and secure support for the further expansion of the Company’s spider silk technologies. He will hold a series of meetings with a contract silk manufacturer with the goal of securing an agreement for 3^rd party silk production. In previous discussions, this manufacturer already outlined a production scale-up plan to produce as much as 200 metric tons of silk per year. Another key goal for this trip will be meetings with Kraig Labs’ joint venture partners, PL Kings, and finalizing plans for the initial product launch under the Spydasilk brand. Rice plans to review textile mills under consideration for the production of the first recombinant spider silk fabric under the Spydasilk brand.

“This is a timely and much-needed trip that will allow us to make the best onsite decisions for Prodigy’s existing operations and the numerous potential expansion opportunities ahead. We’re also excited to bring our US and Vietnam teams together to meet the Company’s evolving needs and address, in person, a diverse list of items that will set the direction of Kraig Labs’ next growth phase,” stated Rice.

The Company is sending its senior scientist, Dr. Miller, to transfer additional process control technologies to the newly formed lab team at Prodigy Textiles, the Company’s wholly-owned Vietnamese subsidiary. Dr. Miller will provide hands-on training for the implementation of several key production initiatives, including the installation of additional laboratory and production equipment, and transferring additional R&D technology. Dr. Miller will devote the majority of his time and efforts to working with new genetic screening protocols and auditing current production processes.

“Dr. Miller’s focus will be on aligning the Prodigy laboratory team members’ efforts with his vision for the laboratory and its role in supporting production growth. This will ensure that the lab team members are optimally trained and positioned to support the production team and cement Prodigy as the top silkworm breeding facility in Vietnam,” concluded Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com